

Neue SIKO-Empfehlungen zum 1. Januar 2024

Literatur

- [1] LeFevre, I., Bravo, L., Folschweiller, N. et al. Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults. *npj Vaccines* 2023; 8: 75; doi: 10.1038/s41541-023-00670-6.
- [2] Angelin M, Sjölin J, Kahn F, et al. Qdenga® - A promising dengue fever vaccine; can it be recommended to non-immune travelers? *Travel Med Infect Dis* 2023; 54: 102598; doi: 10.1016/j.tmaid.2023.102598.
- [3] Nave L, Margalit I, Tau N, et al. Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Vaccines* 2023;11: 1410; doi: 10.3390/vaccines11091410.
- [4] Ramchandani MS, Berzkalns A, Cannon CA, et al. Effectiveness of the Modified Vaccinia Ankara Vaccine Against Mpox in Men Who Have Sex With Men: A Retrospective Cohort Analysis, Seattle, Washington. *Open Forum Infect Dis* 2023; 10: ofad528; doi: 10.1093/ofid/ofad528.
- [5] <https://covariants.org/> (letzter Zugriff: 10. Dezember 2023)
- [6] Maier BF, Rose AH, Burdinski A, et al. Estimating the share of SARS-CoV-2-immunologically naïve individuals in Germany up to June 2022. *Epidemiol Infect* 2023; 151: e38; doi: 10.1017/S0950268823000195.
- [7] Offergeld R, Preußel K, Zeiler T, et al. Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020-2022. *Pathogens* 2023; 12: 551; doi: 10.3390/pathogens12040551.
- [8] Lederer K, Bettini E, Parvathaneni K, et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. *Cell* 2022; 185: 1008-1024.e15; doi: 10.1016/j.cell.2022.01.027.
- [9] Mongin D, Bürgisser N, Laurie G, et al. Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection. *Nat Commun* 2023; 14: 5452; doi: 10.1038/s41467-023-41109-9.
- [10] Papadatou I, Spoulou V. Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right? *Clin Vaccine Immunol* 2016; 23: 388-395; doi: 10.1128/CVI.00721-15.
- [11] Dunne EM, Cilloniz C, von Mollendorf C, et al. Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population? *Arch Bronconeumol* 2023; 59: 157-164; doi: 10.1016/j.arbres.2022.12.015.
- [12] Grant LR, Slack MPE, Theilacker C, et al. Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies. *Vaccine* 2023; 41: 5662-5669; doi: 10.1016/j.vaccine.2023.08.001.
- [13] See KC. Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making. *Vaccines* 2023; 11: 908. doi: 10.3390/vaccines11050908.
- [14] Hennart, M, Crestani, C, Bridel, S, et al. A global *Corynebacterium diphtheriae* genomic framework sheds light on current diphtheria reemergence. *Peer Community J* 2023; e76; doi: 10.24072/pcjournal.307.
- [15] Brémont S, Passet V, Hennart M, et al. Multidrug-resistant *Corynebacterium diphtheriae* in people with travel history from West Africa to France, March to September 2023. *Euro Surveill* 2023; 28: 2300615; doi: 10.2807/1560-7917.ES.2023.28.46.2300615.